Retrospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2021; 9(36): 11248-11254
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11248
Sodium nitroprusside injection immediately before balloon inflation during percutaneous coronary intervention
Yan Yu, Bao-Ping Yang
Yan Yu, Bao-Ping Yang, Department of Cardiovascular Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, Gansu Province, China
Author contributions: Yu Y and Yang BP contributed to the writing and revising of the manuscript.
Supported by 2020 Gansu Planning Projects on Science and Technology, No. 20JR10RA352.
Institutional review board statement: The study was reviewed and approved by the Gansu Provincial Hospital of Traditional Chinese Medicine Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bao-Ping Yang, BSc, Associate Chief Physician, Department of Cardiovascular Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine, No. 418 Guazhou Road, Qilihe District, Lanzhou 730050, Gansu Province, China. ybp1788@163.com
Received: August 10, 2021
Peer-review started: August 10, 2021
First decision: September 2, 2021
Revised: October 7, 2021
Accepted: November 3, 2021
Article in press: November 3, 2021
Published online: December 26, 2021
ARTICLE HIGHLIGHTS
Research background

The incidence of no reflow or slow flow appears to be high in patients with coronary heart disease (CHD) undergoing percutaneous coronary intervention (PCI). This may lead to microvascular obstruction and endothelial disruption. Nipride has been proved effective in treating no reflow or slow flow.

Research motivation

How does sodium nitroprusside benefit in the prevention of no reflow or slow flow? Does the time of administration affect the efficacy of sodium nitroprusside in the prevention of no reflow or slow flow?

Research objectives

The present study was conducted to evaluate efficacy and usefulness of sodium nitroprusside administrated before balloon inflation in prevention of no reflow or slow flow.

Research methods

Patients with CHD undergoing PCI were included. They were divided into two groups. The experimental group received sodium nitroprusside immediately before balloon inflation and the control group received sodium nitroprusside after no reflow or slow flow occurred during the PCI. The incidence of no reflow or slow flow was compared between the two groups. Moreover, thrombolysis in myocardial infarction (TIMI) grade, cardiac function, and adverse events were also compared between the two groups.

Research results

TIMI grade and cardiac function were better in the experimental group than in the control group. The incidence of adverse events was lower in the experimental group than in the control group.

Research conclusions

Sodium nitroprusside administrated immediately before balloon inflation is useful for the prevention of no reflow or slow flow during PCI.

Research perspectives

Long-term, larger sample size and high-quality follow-up RCTs are needed for preventive use of sodium nitroprusside in patients with cardiac disease undergoing PCI.